News
MHRA (UK) grants conditional approval for Nuvaxovid vaccine to prevent COVID-19.- Novavax Inc.
Nuvaxovid, the COVID-19 vaccine developed by Novavax, has been given conditional regulatory approval by the Medicines and Healthcare products Regulatory Agency (MHRA). Nuvaxovid becomes the fifth COVID-19 vaccine authorised by the UK’s independent medicines regulator.
Nuvaxovid is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older.
Condition: Coronavirus/COVID-19 Infection
Type: drug
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.